EFFICACY OF ADJUVANT VERSUS NEOADJUVANT CHEMOTHERAPY IN HISPANIC/LATINO WOMEN WITH EARLY STAGE, TRIPLE NEGATIVE BREAST CANCER (TNBC)

被引：0
|
作者：
Philipovskiy, A. [1 ]
Corral, J. [1 ]
Heydariana, R. [1 ]
Gaur, S. [1 ]
机构：
[1] Texas Tech Univ, Hlth Sci Ctr, El Paso, TX USA
来源：
JOURNAL OF INVESTIGATIVE MEDICINE | 2019年 / 67卷 / 02期
关键词：
D O I：
10.1136/jim-2018-000974.611
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
605
引用
收藏
页码：593 / 593
页数：1
相关论文
共 50 条
  • [21] Clinical and pathological response to neoadjuvant chemotherapy (NCT) in patients with triple negative breast cancer (TNBC)
    Krivorotko, P.
    Zhiltsova, E.
    Gigolaeva, L.
    Emelyanov, A.
    Pesotsky, R.
    Ereschenko, S.
    Levsghenko, V.
    Nikolaev, K.
    Komayachov, A.
    Ivanova, O.
    Tabagua, T.
    Zernov, K.
    Ivanov, V.
    Aseeva, Z.
    Bessonov, A.
    Semiglazov, V.
    BREAST, 2021, 56 : S52 - S52
  • [22] Circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC)
    Lucci, A.
    Hall, C.
    Hess, K.
    Ravenberg, E.
    Clayborn, A.
    Mittendorf, E.
    Rauch, G.
    Candelaria, R.
    Moulder, S.
    Thompson, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [23] Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience
    Vetter, Marcus
    Fokas, Spyridon
    Biskup, Ewelina
    Schmid, Thomas
    Schwab, Fabienne
    Schoetzau, Andreas
    Guth, Uwe
    Rochlitz, Christoph
    Zanetti-Dallenbach, Rosanna
    ONCOTARGET, 2017, 8 (43) : 75617 - 75626
  • [24] A propensity-matched cohort study of neoadjuvant immunotherapy combined with chemotherapy versus neoadjuvant chemotherapy for early-stage triple-negative breast cancer
    Zheng, Chunhui
    Wang, Yongsheng
    Qi, Yingxue
    Song, Yunjie
    Yin, Xiangyu
    Luo, Ningning
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database
    Bagegni, Nusayba A.
    Tao, Yu
    Ademuyiwa, Foluso O.
    PLOS ONE, 2019, 14 (09):
  • [26] Timing of neoadjuvant or adjuvant therapy in patients with early triple negative breast cancer
    Hatzipanagiotou, Maria Eleni
    Pigerl, Miriam
    Gerken, Michael
    Raepple, Sophie
    Zeltner, Verena
    Hetterich, Madeleine
    Ugocsai, Peter
    Inwald, Elisabeth C.
    Klinkhammer-Schalke, Monika
    Seitz, Stephan
    Ortmann, Olaf
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 9 - 9
  • [27] Neoadjuvant and adjuvant treatment for triple negative breast cancer
    Carey, L.
    BREAST, 2021, 56 : S9 - S10
  • [28] Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC).
    Von Minckwitz, Gunter
    O'Shaughnessy, Joyce
    Winer, Eric P.
    Wolmark, Norman
    Geyer, Charles E.
    Huober, Jens Bodo
    Loibl, Sibylle
    Sikov, William M.
    Untch, Michael
    McKee, Mark D.
    Giranda, Vincent L.
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] PARTNER Trial: Neoadjuvant olaparib in triple negative breast cancer (TNBC)
    Abraham, Jean E.
    Pinilla, Karen
    Grybowicz, Louise
    Dayimu, Alimu
    Demiris, Nikolaos
    Harvey, Caron
    Drewett, Lynsey M.
    Lucey, Rebecca
    Fulton, Alexander
    Roberts, Anne N.
    Worley, Joanna R.
    Chhabra, Anita
    Qian, Wendi
    Hardy, Richard M.
    Chan, Stephen
    Hickish, Tamas
    Tripathi, Devashish
    Venkitaraman, Ramachandran
    Persic, Mojca
    Aslam, Shahzeena
    Glassman, Daniel
    Raj, Sanjay
    Borley, Annabel
    Braybrooke, Jeremy P.
    Sutherland, Stephanie
    Staples, Emma
    Scott, Lucy C.
    Davies, Mark
    Palmer, Cheryl A.
    Moody, Margaret
    Churn, Mark J.
    Newby, Jacqueline C.
    Mukesh, B. Mukesh
    Chakrabarti, Amitabha
    Roylance, Rebecca R.
    Schouten, Philip C.
    Levitt, Nicola
    McAdam, Karen
    Armstrong, Anne C.
    Copson, Ellen R.
    McMurtry, Emma
    Tischkowitz, Marc
    Provenzano, Elena
    Earl, Helena
    CANCER RESEARCH, 2024, 84 (07)
  • [30] Outcomes with neoadjuvant versus adjuvant chemotherapy for T1-2 node negative triple negative breast cancer.
    Sharma, Priyanka
    Kimler, Bruce F.
    Klemp, Jennifer R.
    Ward, Claire
    Connor, Carol Sue
    McGinness, Marilee
    Matthew, Joshua
    Mammen, Varghise
    Wagner, Jamie Lynn
    Amin, Amanda Leigh
    Fabian, Carol J.
    Jensen, Roy A.
    Godwin, Andrew K.
    Khan, Qamar J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345